Project Description

Within the framework of the SAGITTARIUS project, researchers aim to optimise the clinical management of locoregional stage II high-risk/stage III colon cancer (LRCC).

Over half of this patient group relapses within two years after treatment due to residual disease that cannot be detected by conventional means. Hence, SAGITTARIUS offers an alternative strategy to detect if any cancer remains in the patient’s body. This strategy involves harnessing the potential presence of tumour-associated DNA. DNA is the genetic material that can be found in the nucleus of cells. In cancer patients, tumour-associated DNA is present in the bloodstream, not just inside the cells. The name of this DNA is circulating tumour DNA (ctDNA).

Because ctDNA may reflect the entire tumour genome, it has gained traction for its potential clinical utility. Liquid biopsies in the form of blood draws taken at various time points can be utilised to monitor tumour progression after treatment. The SAGITTARIUS trial aims to prove the efficacy of using ctDNA detection to guide the clinical management of stage III and high-risk stage II colon cancer patients. The trial will rely on the diagnostic power of ctDNA technology to guide and personalise therapeutic interventions. Based on patient satisfaction, the improvement in diagnosis, treatment, and care will be measured.

Disclaimer: Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.


Funded by
the European Union

This project has received funding from the European Union programme Horizon Europe under Grant Agreement No 101104657)

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.